Our impact
We are committed to funding groundbreaking research aimed at slowing, stopping, or reversing the progression of Parkinson’s.
Through the dedication of our expert committees, collaboration of our partners and the generosity of our supporters, we have directly funded over £25.5 million of research for a cure for Parkinson’s.
Our impact so far
41 institutions awarded funding for research across 12 countries
86+ research projects funded
36 individual drugs being tested across 33 active projects
16 clinical trials directly funded
2,998 people with Parkinson’s taking part in our funded projects
£25.5 million pounds of direct funding committed by Cure Parkinson’s
The impact of our International Linked Clinical Trials (iLCT) programme
The International Linked Clinical Trials programme, led in partnership by Cure Parkinson’s and Van Andel Institute (VAI), is an initiative that brings together leading Parkinson’s experts and advocates to prioritise potentially disease-modifying treatments for clinical evaluation. Many of the drugs prioritised by the iLCT committee have been approved to treat other conditions and passed crucial safety tests, so have potential to get to the clinic much faster.
Since its formation in 2012, the iLCT committee has played a defining role in prioritising and advancing the most promising drug treatments for Parkinson’s. The ongoing aim of the programme is to launch many more clinical trials of both repurposed and novel drugs. Each step should move us closer to the ultimate goal: finding a cure for Parkinson’s.
- As of March 2025, 31% of all drugs in active disease-modifying trials worldwide have been evaluated by the iLCT committee.
- More than £100 million of external funding has been facilitated via the iLCT programme.
- Over 6800 people with Parkinson’s have taken part in clinical trials of drugs evaluated by the iLCT programme.
